Omeros Corporation

About Omeros Corporation

Omeros is advancing novel research and development programs for small-molecule and protein therapeutics to address both orphan and large-market indications. With the successful commercialization of OMIDRIA (phenylephrine and ketorolac intraocular solution) 1%/0.3%, our current areas of focus include complement-mediated diseases, central nervous system disorders and immuno-oncology. Tackling challenging diseases and disorders, we are targeting and exclusively control a broad range of previously untapped receptors and enzymes. The end result is first-in-class therapeutics designed to improve and save the lives of patients.